Wasatch Advisors LP Increases Position in Mesa Laboratories, Inc. $MLAB

Wasatch Advisors LP increased its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 125.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,668 shares of the medical instruments supplier’s stock after acquiring an additional 64,435 shares during the period. Wasatch Advisors LP owned about 2.10% of Mesa Laboratories worth $11,515,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of MLAB. Boston Partners boosted its position in Mesa Laboratories by 2,009.5% in the third quarter. Boston Partners now owns 114,357 shares of the medical instruments supplier’s stock worth $7,664,000 after purchasing an additional 108,936 shares during the last quarter. Millennium Management LLC grew its stake in Mesa Laboratories by 131.9% in the 3rd quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier’s stock valued at $8,967,000 after purchasing an additional 76,107 shares during the period. AQR Capital Management LLC increased its position in shares of Mesa Laboratories by 114.9% during the 4th quarter. AQR Capital Management LLC now owns 70,138 shares of the medical instruments supplier’s stock valued at $5,506,000 after purchasing an additional 37,499 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Mesa Laboratories by 907.1% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 38,842 shares of the medical instruments supplier’s stock valued at $3,049,000 after purchasing an additional 34,985 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its stake in shares of Mesa Laboratories by 34.3% during the 3rd quarter. Kennedy Capital Management LLC now owns 121,546 shares of the medical instruments supplier’s stock worth $8,145,000 after purchasing an additional 31,067 shares during the period. 90.60% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Mesa Laboratories

In other news, CFO John Sakys sold 2,827 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $253,016.50. Following the completion of the transaction, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at $1,770,757.50. This trade represents a 12.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brian David Archbold sold 2,516 shares of Mesa Laboratories stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $225,182.00. Following the completion of the transaction, the senior vice president owned 6,377 shares of the company’s stock, valued at approximately $570,741.50. This trade represents a 28.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 8,277 shares of company stock valued at $770,122 in the last 90 days. 2.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $94.00.

Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB opened at $112.80 on Thursday. The firm has a market capitalization of $631.68 million, a PE ratio of 134.29 and a beta of 0.92. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78. The company has a 50-day moving average price of $100.51 and a two-hundred day moving average price of $95.69. Mesa Laboratories, Inc. has a twelve month low of $58.83 and a twelve month high of $113.99.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter. The company had revenue of $60.14 million for the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.87%.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 dividend on an annualized basis and a yield of 0.6%. Mesa Laboratories’s payout ratio is presently 53.33%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.